Arbutus Q2 FY26 net loss widens to $5.1 million; revenue drops 90.56% to $1.01 million
Reuters2026/08/12 11:37- Arbutus Biopharma posted a Q2 net loss of $5.1 million, swinging from net income of $2.5 million a year earlier.
- Revenue slid 90.56% to $1 million, due to recognition of $9.6 million deferred revenue in Q2 2025 after the Qilu partnership ended.
- R&D expense fell 47.27% to $2.9 million, on workforce reductions, ending in-house research, and lower clinical trial costs.
- Cash, cash equivalents and marketable securities totaled $92.6 million at June 30, 2026; received $178.4 million in July from the Moderna settlement.
- Plans to repurchase up to about $230 million of shares starting Q3; filed international patent enforcement suits against Pfizer and BioNTech.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Why hasn’t the rise in US Treasury yields boosted the US dollar exchange rate?
Gurman predicts iPhone Duo: The first foldable may set industry standards, Apple (AAPL.US) foldable could trigger a decade-long upgrade cycle
Renowned financial journalist Mark Gurman stated that Apple’s first foldable iPhone has the potential to elevate the still-experimental foldable phone category to an industry standard. He noted that this device, called the iPhone Duo, is one of Apple’s most influential products, ranking just behind the iMac, iPod, iPad, and Apple Watch.
Element Fleet drops bid for FleetPartners, exits sale process
Anchoring to Nasdaq! Anthropic races toward a record-breaking IPO with fundraising scale targeting SpaceX
Sources indicate that Anthropic PBC has chosen Nasdaq as its listing venue, and the potential IPO is expected to set a historic record.
Crypto prices
More
